首页> 外文OA文献 >The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation

【2h】

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation

机译：Mirabegron在儿童和青少年中的药代动力学，安全性和耐受性，具有神经源性排尿管过度或特发性过度活性膀胱和基于人口药代动力学模型的儿科剂量估算的发展

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Søren Rittig; Małgorzata Baka-Ostrowska; Camilla Tøndel; Johan Vande Walle; Birgitta Kjaeer; Paul Passier; Brigitte Bosman; Otto Stroosma; Stacey Tannenbaum;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation [J] . Journal of pediatric urology . 2020,第1期

机译：Mirabegron在儿童和青少年中的药代动力学，安全性和耐受性，具有神经源性排尿管过度或特发性过度活性膀胱和基于人口药代动力学模型的儿科剂量估算的发展
2. A MULTICENTER, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF SOLIFENACIN SUCCINATE SUSPENSION IN PEDIATRIC SUBJECTS FROM 5 TO LESS THAN 18 YEARS OF AGE WITH NEUROGENIC DETRUSOR OVERACTIVITY (NDO). [J] . Bosman B., Tannenbaum S., Winklewski P., Neurourology and urodynamics. . 2013,第6期

机译：多中心，开放式，单剂量研究评估小儿科受试者中5到18岁以下神经原性胶体活动过度的药动学，安全性和耐受性甜菜碱糖苷悬浮液的耐受性。
3. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity [J] . Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, Pharmacology Research & Perspectives . 2020,第6期

机译：索尔替芬素的药代动力学在具有过热膀胱或神经源性排尿管过度的儿科群体中的药代动力学
4. Applications of Physiologically Based Pharmacokinetic Modelling to Prediction of the Likelihood of Metabolic Drug Interactions in Paediatric Population and Studying Disparities in Pharmacokinetics Between Children and Adults [D] . Salem, Farzaneh. 2014

机译：基于生理的药代动力学模型在小儿人群中代谢药物相互作用的可能性预测和研究儿童与成人之间药代动力学差异的应用
5. Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity [O] . Stacey Tannenbaum, Martin den Adel, Walter Krauwinkel, 2020

机译：索尔替芬素的药代动力学在具有过热膀胱或神经源性排尿管过度的儿科群体中的药代动力学
6. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study [O] . Małgorzata Baka‐Ostrowska, David T. Bolong, Cristian Persu, 2021

机译：Mirabegron在具有神经源性戒烟过度的儿童和青少年的疗效和安全性：开放标签，第3期，剂量滴定研究

The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation

著录项

引文网络

相似文献

相关主题

期刊订阅